Breast cancer patients to have routine access to two life extending drugs after new deal say NICE
NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave more evidence for their effectiveness.
Source: NHS Networks - Category: UK Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Funding | National Institute for Health and Clinical Excelle | UK Health